# ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Study · id `cardio:ct-nct05746559` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05746559](<https://clinicaltrials.gov/study/NCT05746559>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05746559

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 555 participants.

## Technical summary

Registry record NCT05746559. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-06 (actual); primary completion 2025-10-07 (actual). Results posted on 2026-10-29.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 555 participants (enrolled count; ClinicalTrials.gov record NCT05746559, source copy `cardio:ctgov-nct05746559-2026-10-29`, retrieved 2026-10-31)
- Started: 2023-04-06 (actual) (ClinicalTrials.gov record NCT05746559, source copy `cardio:ctgov-nct05746559-2026-10-29`, retrieved 2026-10-31)
- Primary completion: 2025-10-07 (actual) (ClinicalTrials.gov record NCT05746559, source copy `cardio:ctgov-nct05746559-2026-10-29`, retrieved 2026-10-31)
- Completion: 2026-05-07 (actual) (ClinicalTrials.gov record NCT05746559, source copy `cardio:ctgov-nct05746559-2026-10-29`, retrieved 2026-10-31)
- Results first posted: 2026-10-29 (ClinicalTrials.gov record NCT05746559, source copy `cardio:ctgov-nct05746559-2026-10-29`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Brazil; Canada; China; France; Germany; Hong Kong SAR China; India; Israel; Italy; Japan; Netherlands; Poland; South Korea; Spain; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05746559, source copy `cardio:ctgov-nct05746559-2026-10-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05746559-2026-10-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
- Acronym: ARTEMIS
- Condition: Chronic Kidney Disease
- Condition: CKD
- Condition: Cardiac Disease
- Condition: Cardiopulmonary Bypass
- Intervention (Drug): Placebo
- Intervention (Drug): Ravulizumab
- Lead sponsor: Alexion Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Alexion Pharmaceuticals, Inc. (`cardio:org-alexion-pharmaceuticals-inc`)

## Provenance

Content hash: 12ab31c4c470df5795d53147567190cbd8fb9c248e6cf442f2710a2579c5a715
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
